Hengtong(SH:600226) Shang Hai Zheng Quan Bao·2025-11-19 18:00Core Viewpoint - The company has provided guarantees for its wholly-owned subsidiaries, Hengtong Precision Copper Foil Technology (Deyang) Co., Ltd. and Zhejiang Baike Biotechnology Co., Ltd., to support their operational funding needs through loans from banks [2][9]. Group 1: Guarantee Details - The company signed a guarantee contract with Bank of China Chengdu Longquanyi Branch to provide a joint liability guarantee for a loan of RMB 100 million (10,000 million) for Hengtong Copper Foil [2][7]. - A maximum guarantee contract was signed with Jiaxing Bank Anji Branch for a credit of RMB 50 million (5,000 million) for Baike Biotechnology [2][8]. - The guarantee period for both contracts is three years from the maturity of the debt [7][8]. Group 2: Internal Decision-Making Process - The company's board of directors and the fourth extraordinary general meeting of shareholders approved the proposal to provide guarantees for the subsidiaries, with authorized limits of RMB 900 million (90,000 million) for Hengtong Copper Foil and RMB 300 million (30,000 million) for Baike Biotechnology [3][10]. - The guarantees fall within the limits approved by the shareholders' meeting, eliminating the need for additional board or shareholder meetings [4]. Group 3: Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to meet the operational funding needs of the subsidiaries and to facilitate the company's transformation and development [9]. - The subsidiaries are reported to have normal operations and good credit status, making the risks associated with the guarantees controllable [9][11]. Group 4: Cumulative Guarantee Situation - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is RMB 436.6458 million (43,664.58 million), accounting for 12.79% of the company's audited net assets for 2024 [11]. - The actual guarantee amount for Hengtong Copper Foil is RMB 386.6458 million (38,664.58 million), representing 11.32% of the company's audited net assets, while for Baike Biotechnology, it is RMB 50 million (5,000.00 million), accounting for 1.46% [11].